Bile acids promote HCV replication through the EGFR/ERK pathway in replicon-harboring cells

Area of Science:

• Hepatology
• Virology
• Molecular Biology

Background:

• Bile acids are known to influence viral replication.
• Interferon-alpha (IFN-α) is a key antiviral therapy for Hepatitis C Virus (HCV).
• The precise mechanisms by which bile acids affect HCV replication and IFN-α efficacy are not fully understood.

Purpose of the Study:

• To investigate the role of bile acids in promoting HCV replication.
• To explore the involvement of the epidermal growth factor receptor (EGFR) and extracellular signal-regulated kinase (ERK) pathway in bile acid-mediated HCV replication.
• To determine if EGFR or ERK inhibition can restore the anti-HCV effects of IFN-α.

Main Methods:

• HCV replicon-harboring cells were treated with bile acids, IFN-α, and specific inhibitors (AG1478 for EGFR, U0126 for ERK).
• Cell cycle analysis, quantitative reverse transcription polymerase chain reaction (qRT-PCR), and Western blot analysis were used to measure treatment effects.
• Combinatorial treatments assessed the impact on viral replication and IFN-α efficacy.

Main Results:

• Bile acids activated the EGFR/ERK pathway and prolonged the S-phase of cells, correlating with increased HCV replication.
• EGFR inhibitor AG1478 and ERK inhibitor U0126 significantly reduced bile acid-induced HCV replication.
• Co-administration of AG1478 or U0126 with bile acids and IFN-α restored the antiviral activity of IFN-α.

Conclusions:

• Bile acids promote HCV replication through EGFR/ERK pathway activation.
• Inhibiting EGFR or ERK can counteract the pro-viral effects of bile acids.
• Combining EGFR or ERK inhibitors with IFN-α may enhance treatment outcomes for HCV.